Andamertinib Benzoate

苯甲酸安达艾替尼

Report date: 2026/05/27 14:23:30
NME

Base Information

Drug NameAndamertinib Benzoate
Drug Alias Name安达艾替尼Andamertinib苯甲酸安达替尼安比锐PLB-1004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR exon 20 insertion mutations inhibitorsEGFR 19del inhibitorsEGFR L858R inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2EGFR exon 20 insertion mutations +[5] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2026/04/29
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Avistone Pharmaceuticals Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSaddle Stone Pharmaceutical (Ningbo) Co LtdBeijing Avistone Pharmaceuticals Biotechnology Co Ltd
Inactive CompaniesAsymchem Life Science (Tianjin) Co Ltd
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A